Blog
New
Breast Cancer Screening with Sequence Transduction Technology
Breast Cancer Screening with Sequence Transduction Technology
Rita Bhui
5 Min Read
Share
Imagine this
A patient comes in for a routine breast cancer screening. She has no symptoms, no family history, and feels perfectly healthy. Like millions of women worldwide, she's participating in early detection—the most powerful weapon against breast cancer. Yet current screening methods have limitations: mammograms can miss up to 20% of breast cancers, especially in women with dense breast tissue, and molecular testing for genetic markers is often reserved for high-risk cases due to cost and complexity.
What if we could make comprehensive molecular screening as routine and accessible as a mammogram?
What is Breast Cancer Screening?
Breast cancer screening involves checking a woman's breasts for cancer before there are signs or symptoms. The goal is simple: find cancer early, when it's most treatable.
According to global health statistics:
Breast cancer is the most common cancer in women worldwide
Early detection can increase 5-year survival rates to over 90%
About 1 in 8 women will develop breast cancer in their lifetime
Why is Comprehensive Screening So Challenging?
The limitations of current approaches create significant gaps:
Imaging limitations – Mammograms can miss cancers in dense breast tissue and sometimes yield false positives
Genetic testing barriers – BRCA and other genetic tests are expensive and typically only offered to high-risk patients
Molecular complexity – Breast cancer involves multiple genetic markers beyond just BRCA1/2
Access and cost – Advanced molecular profiling isn't available for routine population screening
Current Screening Methods
Mammography: The standard imaging method, but limited by breast density and radiation exposure
Ultrasound/MRI: Used as supplemental screening, especially for high-risk women, but expensive and time-consuming
Genetic Testing: Typically targets only BRCA1/2 and a few other high-risk genes
Liquid Biopsy: Emerging technology that detects cancer DNA in blood, but still costly for screening
How AlgoBio's Breast Cancer Screening Panel Can Help
At AlgoBio, we're developing a comprehensive molecular screening platform that addresses the critical need for accessible, broad-based genetic risk assessment. Using our Sequence Transduction technology, we're creating a highly multiplexed panel that can:
Screen for dozens of breast cancer-associated genes simultaneously, going beyond the usual BRCA1/2 suspects
Detect both inherited mutations and somatic changes that may indicate early cancer development
Provide risk stratification to help identify women who need more frequent or intensive monitoring
The vision is transformative: make comprehensive molecular screening available to every woman, not just those with known risk factors.
Here's how our approach changes breast cancer detection:
Comprehensive coverage: Test for multiple genetic markers in one affordable assay, rather than sequential single-gene tests
Early detection focus: Identify molecular changes before they become visible on imaging
Scalability: Algorithm-driven design makes population-level screening economically feasible
Personalized follow-up: Results guide appropriate next steps—from more frequent screening to preventive measures
Future adaptability: Easily incorporate new biomarkers as research advances
With this technology, AlgoBio's Breast Cancer Screening Panel doesn't just detect risk—it empowers women and their doctors with actionable information to stay ahead of cancer.
Why This Matters
With more accessible molecular screening, healthcare providers can:
Identify high-risk women earlier, before cancer develops
Reduce unnecessary anxiety from false positives through more precise risk assessment
Enable personalized screening schedules based on individual genetic risk
Ultimately save lives through earlier detection and intervention
Looking Ahead
Breast cancer doesn't announce itself with obvious symptoms in the early stages. But with innovations like AlgoBio's Screening Panel, we're moving closer to a world where comprehensive molecular risk assessment is part of routine women's healthcare.
By combining advanced genetic analysis with scalable, affordable technology, we're building screening tools that can reach every woman, in every community.
Early detection saves lives—and now, we can detect even earlier.
More Article
Imagine this
A patient comes in for a routine breast cancer screening. She has no symptoms, no family history, and feels perfectly healthy. Like millions of women worldwide, she's participating in early detection—the most powerful weapon against breast cancer. Yet current screening methods have limitations: mammograms can miss up to 20% of breast cancers, especially in women with dense breast tissue, and molecular testing for genetic markers is often reserved for high-risk cases due to cost and complexity.
What if we could make comprehensive molecular screening as routine and accessible as a mammogram?
What is Breast Cancer Screening?
Breast cancer screening involves checking a woman's breasts for cancer before there are signs or symptoms. The goal is simple: find cancer early, when it's most treatable.
According to global health statistics:
Breast cancer is the most common cancer in women worldwide
Early detection can increase 5-year survival rates to over 90%
About 1 in 8 women will develop breast cancer in their lifetime
Why is Comprehensive Screening So Challenging?
The limitations of current approaches create significant gaps:
Imaging limitations – Mammograms can miss cancers in dense breast tissue and sometimes yield false positives
Genetic testing barriers – BRCA and other genetic tests are expensive and typically only offered to high-risk patients
Molecular complexity – Breast cancer involves multiple genetic markers beyond just BRCA1/2
Access and cost – Advanced molecular profiling isn't available for routine population screening
Current Screening Methods
Mammography: The standard imaging method, but limited by breast density and radiation exposure
Ultrasound/MRI: Used as supplemental screening, especially for high-risk women, but expensive and time-consuming
Genetic Testing: Typically targets only BRCA1/2 and a few other high-risk genes
Liquid Biopsy: Emerging technology that detects cancer DNA in blood, but still costly for screening
How AlgoBio's Breast Cancer Screening Panel Can Help
At AlgoBio, we're developing a comprehensive molecular screening platform that addresses the critical need for accessible, broad-based genetic risk assessment. Using our Sequence Transduction technology, we're creating a highly multiplexed panel that can:
Screen for dozens of breast cancer-associated genes simultaneously, going beyond the usual BRCA1/2 suspects
Detect both inherited mutations and somatic changes that may indicate early cancer development
Provide risk stratification to help identify women who need more frequent or intensive monitoring
The vision is transformative: make comprehensive molecular screening available to every woman, not just those with known risk factors.
Here's how our approach changes breast cancer detection:
Comprehensive coverage: Test for multiple genetic markers in one affordable assay, rather than sequential single-gene tests
Early detection focus: Identify molecular changes before they become visible on imaging
Scalability: Algorithm-driven design makes population-level screening economically feasible
Personalized follow-up: Results guide appropriate next steps—from more frequent screening to preventive measures
Future adaptability: Easily incorporate new biomarkers as research advances
With this technology, AlgoBio's Breast Cancer Screening Panel doesn't just detect risk—it empowers women and their doctors with actionable information to stay ahead of cancer.
Why This Matters
With more accessible molecular screening, healthcare providers can:
Identify high-risk women earlier, before cancer develops
Reduce unnecessary anxiety from false positives through more precise risk assessment
Enable personalized screening schedules based on individual genetic risk
Ultimately save lives through earlier detection and intervention
Looking Ahead
Breast cancer doesn't announce itself with obvious symptoms in the early stages. But with innovations like AlgoBio's Screening Panel, we're moving closer to a world where comprehensive molecular risk assessment is part of routine women's healthcare.
By combining advanced genetic analysis with scalable, affordable technology, we're building screening tools that can reach every woman, in every community.
Early detection saves lives—and now, we can detect even earlier.
More Article
Imagine this
A patient comes in for a routine breast cancer screening. She has no symptoms, no family history, and feels perfectly healthy. Like millions of women worldwide, she's participating in early detection—the most powerful weapon against breast cancer. Yet current screening methods have limitations: mammograms can miss up to 20% of breast cancers, especially in women with dense breast tissue, and molecular testing for genetic markers is often reserved for high-risk cases due to cost and complexity.
What if we could make comprehensive molecular screening as routine and accessible as a mammogram?
What is Breast Cancer Screening?
Breast cancer screening involves checking a woman's breasts for cancer before there are signs or symptoms. The goal is simple: find cancer early, when it's most treatable.
According to global health statistics:
Breast cancer is the most common cancer in women worldwide
Early detection can increase 5-year survival rates to over 90%
About 1 in 8 women will develop breast cancer in their lifetime
Why is Comprehensive Screening So Challenging?
The limitations of current approaches create significant gaps:
Imaging limitations – Mammograms can miss cancers in dense breast tissue and sometimes yield false positives
Genetic testing barriers – BRCA and other genetic tests are expensive and typically only offered to high-risk patients
Molecular complexity – Breast cancer involves multiple genetic markers beyond just BRCA1/2
Access and cost – Advanced molecular profiling isn't available for routine population screening
Current Screening Methods
Mammography: The standard imaging method, but limited by breast density and radiation exposure
Ultrasound/MRI: Used as supplemental screening, especially for high-risk women, but expensive and time-consuming
Genetic Testing: Typically targets only BRCA1/2 and a few other high-risk genes
Liquid Biopsy: Emerging technology that detects cancer DNA in blood, but still costly for screening
How AlgoBio's Breast Cancer Screening Panel Can Help
At AlgoBio, we're developing a comprehensive molecular screening platform that addresses the critical need for accessible, broad-based genetic risk assessment. Using our Sequence Transduction technology, we're creating a highly multiplexed panel that can:
Screen for dozens of breast cancer-associated genes simultaneously, going beyond the usual BRCA1/2 suspects
Detect both inherited mutations and somatic changes that may indicate early cancer development
Provide risk stratification to help identify women who need more frequent or intensive monitoring
The vision is transformative: make comprehensive molecular screening available to every woman, not just those with known risk factors.
Here's how our approach changes breast cancer detection:
Comprehensive coverage: Test for multiple genetic markers in one affordable assay, rather than sequential single-gene tests
Early detection focus: Identify molecular changes before they become visible on imaging
Scalability: Algorithm-driven design makes population-level screening economically feasible
Personalized follow-up: Results guide appropriate next steps—from more frequent screening to preventive measures
Future adaptability: Easily incorporate new biomarkers as research advances
With this technology, AlgoBio's Breast Cancer Screening Panel doesn't just detect risk—it empowers women and their doctors with actionable information to stay ahead of cancer.
Why This Matters
With more accessible molecular screening, healthcare providers can:
Identify high-risk women earlier, before cancer develops
Reduce unnecessary anxiety from false positives through more precise risk assessment
Enable personalized screening schedules based on individual genetic risk
Ultimately save lives through earlier detection and intervention
Looking Ahead
Breast cancer doesn't announce itself with obvious symptoms in the early stages. But with innovations like AlgoBio's Screening Panel, we're moving closer to a world where comprehensive molecular risk assessment is part of routine women's healthcare.
By combining advanced genetic analysis with scalable, affordable technology, we're building screening tools that can reach every woman, in every community.
Early detection saves lives—and now, we can detect even earlier.